Brief: BioArctic Says Sales Of Leqembi Reached EUR 200 Million In Eisai FY 2024
Feb 18 (Reuters) - BioArctic AB BIOAb.ST :
* LEQEMBI® SALES REACHES €200 MILLION - FIRST SALES
MILESTONE
ACHIEVED
* BIOARCTIC AB - MILESTONE WAS REACHED AS SALES OF LEQEMBI
REACHED
EUR 200 MILLION IN EISAI FISCAL YEAR 2024
Source text: ID:nPn3RRJHVa
Further company coverage: BIOAb.ST
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eisai
See all newsBiogen tops quarterly estimates on rare-disease drug strength (updated)
Biogen beats third-quarter results on strength in rare disease drugs
Brief: FDA Approves Belzutifan-Lenvatinib Combination for Advanced Renal Cell Carcinoma With A Clear Cell Component
Leqembi Pen (Subcutaneous Formulation Of Leqembi) Approved In Japan
Leqembi (Lecanemab) Subcutaneous Formulation As An Initiation Treatment For Early Alzheimer's Disease Approved In China